Glenmark Pharmaceuticals Inc., USA has announced the launch of its Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the United States. This bioequivalent and therapeutically equivalent product targets the market previously dominated by ProvayBlue® Injection. The launch signifies Glenmark’s commitment to expanding access to quality, affordable medicines in the U.S. institutional sector, aligning with its strategic focus on innovation and accessibility.
Glenmark Pharmaceuticals Inc., USA Launches Methylene Blue Injection USP
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has officially launched its Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the United States. The announcement was made on June 17, 2026.
Product Equivalence and Market Potential
Glenmark’s Methylene Blue Injection USP has been confirmed to be bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), manufactured by Provepharm SAS (NDA 204630). According to IQVIA® sales data, the market for ProvayBlue® Injection achieved annual sales of approximately $19.0 million for the 12-month period ending April 2026. This launch aims to capture a share of this significant market.
Strategic Importance and Market Access
Marc Kikuchi, President & Business Head, North America at Glenmark, commented on the launch, stating, “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.”
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company focused on innovation and accessibility. With a diversified portfolio across branded, innovative, generics, and consumer health products, the company aims to pioneer transformative therapies and expand access to high-quality, affordable medicines worldwide. Glenmark has a commercial footprint in over 80 countries and is recognized among the Top 100 biopharmaceutical companies globally by pharmaceutical sales.
Contact Information
For more information, please contact:
India
Akhila Natarajan
[email protected]
+91 22 4018 9999
Adfactors PR
[email protected]
United States
Akhila Natarajan
[email protected]
Danielle Hagen
[email protected]
202-365-6112
Source: BSE
